DEVELOPER OF BREAKTHROUGH BIOTHERAPEUTICS FOR B CELL CANCERS, METABOLIC DISEASES, AND CHRONIC HEPATITIS B INFECTIONS
About Ancora Biotech
Ancora Biotech LLC is a privately held company supporting the clinical development of three multi-specific antibodies. These three antibodies are held in separate spin-offs, namely: 1) TeneoTwo holds our clinical stage TNB-486 (anti-CD19xCD3) T cell engager for the safe and effective treatment of B cell cancers, 2) TeneoFour holds our preclinical TNB-738 (anti-CD38) enzyme inhibitor for the treatment of inflammatory and metabolic disorders in the elderly, and 3) TeneoTen holds our preclinical T cell engager (anti-HBVxCD3) for the curative treatment of chronic hepatitis B infections (CHB). TNB-738 is poised to enter Phase I clinical studies by early 2022 and we anticipate to select a clinical lead for CHB by mid-2022.
Certain former executives and former shareholders of Teneobio, including Lightspeed Venture Partners and Sutter Hill Ventures, have formed Ancora Biotech to oversee all manufacturing and clinical development of these assets.
TNB-738, a biparatopic antibody, boosts intracellular NAD+ by inhibiting CD38 ecto-enzyme activity
ABSTRACT Cluster of differentiation 38 (CD38) is an ecto-enzyme expressed primarily on immune cells that metabolize nicotinamide
How Venture Capitalists Made Bet on Drugmaker Teneobio Pay Off
Investment in the startup has led to a series of profitable deals, including one with AstraZeneca worthnearly
Ancora Biotech: TeneoTwo Acquisition & What’s Next
Original Article By Galym Imanbayev and Jonathan MacQuitty - on Medium Today, AstraZeneca announced its agreement to acquire